Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04688671
Other study ID # ETX-018810-202
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 9, 2020
Est. completion date February 18, 2022

Study information

Verified date November 2023
Source Eliem Therapeutics (UK) Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects with Diabetic Peripheral Neuropathic Pain.


Description:

ETX-018810 is a new chemical entity that is under development as a non-opioid treatment for chronic pain syndromes. ETX-018810 is a prodrug of palmitoylethanolamide (PEA), an endogenous bioactive lipid that has shown efficacy in a broad range of nonclinical inflammatory and neuropathic pain models and in clinical trials in chronic pain indications, including diabetic peripheral neuropathic pain (DPNP).


Recruitment information / eligibility

Status Completed
Enrollment 167
Est. completion date February 18, 2022
Est. primary completion date February 9, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - The subject is =18 and =75 years of age at the time of signing ICF. - The subject has a diagnosis of type 1 or 2 diabetes mellitus. - The subject has diabetic neuropathy of a symmetrical nature in the lower extremities for =6 months to =10 years - The subject reports at least moderate pain intensity - The subject's onset of neuropathic pain is at least 3 months before the screening visit. - The subject has used a stable regimen of antidiabetic agents for at least 1 month before the baseline visit or has achieved adequate glycemic control through diet and exercise. - The subject has clinical laboratory values within normal limits or abnormal values that the investigator deems not clinically significant. - Sexually active male subjects with female partners of childbearing potential and sexually active female subjects of childbearing potential must agree to practice effective contraception or to remain abstinent during the study and for 4 weeks after the last dose of investigational product - The subject is capable of giving signed informed consent and agrees to provide authorization for use and release of health records. Exclusion Criteria: - The subject has pain that cannot be clearly differentiated from or that could interfere with the assessment of DPNP. - The subject has neurologic and/or circulatory disorders that are unrelated to diabetic neuropathy - The subject has a history of hypoglycemia that disturbed consciousness or ketoacidosis that required hospitalization within the 3 months before screening. - The subject has clinically significant and/or unstable renal, hepatic, hematologic, immunologic, inflammatory/rheumatologic, respiratory, or cardiovascular disease that would compromise participation in the study in the judgment of the investigator. - The subject has any neurological disease that could interfere with participation in the study (eg, Huntington's disease, Parkinson's disease, Alzheimer's disease, multiple sclerosis, seizures, epilepsy, stroke). - The subject has an amputation of a lower extremity. Toe amputation is allowed. - The subject has clinically significant abnormal electrocardiogram (ECG) findings at screening or baseline. - The subject is likely to require major surgery during the study. - The subject is pregnant or lactating. - The subject is unwilling or unable to discontinue current medications for neuropathic pain, including topical agents. - The subject is unable to refrain from using nonsteroidal anti-inflammatory drugs (NSAIDs); antiepileptic drugs, steroids, cannabinoids, or major opioids, muscle relaxants, tramadol, or tapentadol throughout the study. - The subject has used prohibited nonpharmacologic therapies, including acupuncture, transcutaneous electrical nerve stimulation, etc, within 30 days before baseline/Day 1 or anticipates use of such therapies during the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ETX-018810
Study Drug
Placebo
Matching Placebo

Locations

Country Name City State
United States FutureSearch Trials of Neurology Austin Texas
United States Northwest Clinical Research Center Bellevue Washington
United States Hassman Research Institute Berlin New Jersey
United States Alpine Research Organization Clinton Utah
United States Midwest Clinical Research Center Dayton Ohio
United States Medisphere Medical Research Center Evansville Indiana
United States Neuro-Pain Medical Cneter Fresno California
United States Chase Medical Research LLC Hamden Connecticut
United States Charter Research Lady Lake Florida
United States Alliance for Multispeciality Research LLC Las Vegas Nevada
United States Coral Research Clinic Corp Miami Florida
United States Cordova Research Institute Miami Florida
United States Delta Clinical Research Mobile Alabama
United States IMA Clinical Research New York New York
United States Better Health Clinical Reseach Newnan Georgia
United States Arizona Research Center Phoenix Arizona
United States StudyMetrix Research LLC Saint Peters Missouri
United States Jean Brown Research Salt Lake City Utah
United States Wasatch Clinical Research LLC Salt Lake City Utah
United States Encompass Clinical Research Spring Valley California
United States Diabetes Research Center Tustin California
United States Upstate Clinical Research Associates Williamsville New York

Sponsors (1)

Lead Sponsor Collaborator
Eliem Therapeutics (UK) Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline to Week 4 in the Weekly Average of the Daily Pain Score as Derived From the Subject's Responses on the Pain Intensity Numerical Rating Scale (PI-NRS) Change from baseline in the weekly average of the daily pain score as derived from the subject's responses on the Pain Intensity Numerical Rating Scale (PI-NRS) a 10 point scale from 0 being the least (No Pain) to 10 being the most (Worst Possible Pain). baseline to Week 4
Secondary Number of Subjects With a =50% Reduction From Baseline to Weeks 1, 2, 3, and 4 in the Weekly Average of the Daily Pain Score Change in the weekly average of the daily pain score as derived from the subject's responses on the Pain Intensity Numerical Rating Scale (PI-NRS) a 10 point scale from 0 being the least (No Pain) to 10 being the most (Worst Possible Pain). Baseline to Weeks 1, 2, 3 and 4
Secondary Number of Subjects With a =30% Reduction From Baseline to Weeks 1, 2, 3, and 4 in the Weekly Average of the Daily Pain Score Change in the weekly average of the daily pain score as derived from the subject's responses on the Pain Intensity Numerical Rating Scale (PI-NRS) a 10 point scale from 0 being the least (No Pain) to 10 being the most (Worst Possible Pain). Baseline to Weeks 1, 2, 3 and 4
Secondary Change in the Weekly Average of the Daily Pain Score From Baseline to Weeks 1, 2, and 3 Change in the weekly average of the daily pain score as derived from the subject's responses on the Pain Intensity Numerical Rating Scale (PI-NRS) a 10 point scale from 0 being the least (No Pain) to 10 being the most (Worst Possible Pain). Baseline to Weeks 1, 2 and 3
Secondary Number of Subjects With a CGI-C Response (Defined as "Much Improved" or "Very Much Improved") at Week 4 The Clinical Global Impression - Change (CGI-C) is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to the baseline state at the beginning of the intervention. The rater selects one response based on the following question, "Compared to your patient's condition at the beginning of treatment, how much has your patient changed?" Scores are as follows: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; and 7 = very much worse. Week 4
Secondary Number of Subjects With a PGI-C Response (Defined as "Much Improved" or "Very Much Improved") at Week 4. The Patient Global Impression - Change (PGI-C) is the patient-reported counterpoint to the CGI C (Guy, 1976). The qualitative assessment of meaningful change is determined by the patient in response to the question, "Compared to your condition at the beginning of treatment, how much has your condition changed?" Scores are as follows: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; and 7 = very much worse. Week 4
Secondary Change in the Weekly Average of the Daily Sleep Score on the DSIS From Baseline to Weeks 1, 2, 3, and 4 The Daily Sleep Interference Scale (DSIS) is an 11-point response scale that quantifies sleep interference due to pain. It is a single-item measure that is completed once daily, upon awakening, to accurately capture variability in sleep interference due to pain on a daily basis, thus minimizing recall bias. Patients are asked to select the number that best describes how much their pain has interfered with their sleep during the last 24 hours on a scale from 0 (pain does not interfere with sleep) to 10 (pain completely interferes with sleep). Baseline to Weeks 1, 2, 3 and 4
Secondary Change in the BPI - Interference Scale From Baseline to Week 4 The BPI Interference scale measures how much pain has interfered with seven daily activities scored on a scale from 0 (does not interfere) to 10 (completely interferes). It is scored as the mean of the seven interference items. Baseline to Week 4
Secondary Change in the BPI-Pain Scale From Baseline to Week 4 The BPI pain scale is a composite of 4 items assessing pain severity (worst, least, average, and right now). Subjects rate their pain in last 24 hours on a scale from 0 (no pain) to 10 (pain as bad as you can imagine). It is scored as the mean of the four pain items. Baseline to Week 4
Secondary Change in the Daily Amount of Acetaminophen Use From Baseline to Week 4 The daily amount of acetaminophen (rescue medication) that was used (mg per day). Baseline to week 4
See also
  Status Clinical Trial Phase
Recruiting NCT04638556 - Effect of Circulating lncRNAs on Type 2 Diabetic Peripheral Neuropathy
Completed NCT05580705 - Effects of Vibration Therapy in Addition to Routine Physical Therapy in Patients With Diabetic Neuropathy N/A
Terminated NCT01620775 - MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain N/A
Completed NCT02127762 - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy N/A
Completed NCT00835757 - Diffusion Tensor Imaging of Sural Nerves in Diabetic Peripheral Neuropathy N/A
Recruiting NCT00553592 - Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes Phase 2
Recruiting NCT05863793 - Clinical Study of Acupuncture in the Treatment of Diabetic Peripheral Neuropathy N/A
Withdrawn NCT05041816 - Peripheral Nerve Responses to Focal Vibration and Implications in Pain and Mobility for Patients With Diabetic Peripheral Neuropathy N/A
Recruiting NCT06074562 - A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain Phase 2
Recruiting NCT04457531 - LiuWeiLuoBi Granule for the Treatment of Diabetic Peripheral Neuropathy Early Phase 1
Completed NCT02947828 - Polyneuropathy in Diabetes Mellitus Type 2
Completed NCT02056431 - Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy N/A
Completed NCT01681290 - Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes Phase 2
Completed NCT01474772 - Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN) Phase 3
Completed NCT01086150 - Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy Phase 2/Phase 3
Completed NCT03447756 - Titration Study of ABX-1431 Phase 1
Completed NCT04984044 - Effect of Vitamin D in Patients With Diabetic Peripheral Neuropathy to Alleviate Pain and Improvement of Symptoms N/A
Completed NCT06130917 - Effects of Multisystem Exercise on Balance, Postural Stability, Mobility and Pain in Patients With DPN. N/A
Completed NCT01496365 - Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy Phase 2
Completed NCT02332005 - 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study Phase 2/Phase 3